Latest Breaking News On - Clinical immunology - Page 3 : comparemela.com

We're the 'allergy capital of the world'. But we don't know why food allergies are so common in Australian children

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 - Jasper Therapeutics (NASDAQ:JSPR)

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting

We're the 'allergy capital of the world'. But we don't know why food allergies are so common in Australian children | Jennifer Koplin and Desalegn Markos Shifti for the Conversation

Vitamin D levels, sanitation, diet and migration patterns are all thought to play a role. But there are trials under way to develop new strategies to prevent food allergies

Allergy Therapeutics presents findings at EAACI | Company Announcement

Investegate announcements from Allergy Therapeutics presents findings at EAACI

Novartis: efficacy of remibrutinib in urticaria -USC

Phase III data from Novartis confirm the durable efficacy and long-term safety of oral remibrutinib in the treatment of chronic spontaneous urticaria .In the pivotal Phase III REMIX-1 and REMIX-2.